Investor Presentation

NHTUHHL 150 150 e F\l)\OeSE N<" c fl P S U Le S Q9qu0a0l1ky :2015 e}n1v4i0r0o1nm e:n2t0a1l5 ] ey" +% -o i Management// Management // Hiah &55fe F L %, & e g gy LIMITGD VG - Caps CORP & REGD OFFICE : “ TRIDENT TOWERS” No. 23. 4th Floor, 100 2nd Block, Bangalore-560011 Phone : 080-26561562 / 1571 /1573 /581 URL : www.naturalcapsules.com Email : infot@naturalcapsule: om, CIN No. : LRS1T0KA1993PLCO14742 Date: August 13, 2026 To To BSE Limited National Stock Exchange of India Limited 25th Floor, PJ Towers Exchange Plaza, C-1, Block G Dalal Street, Bandra Kurla Complex, Bandra (E) Mumbai — 400001 Mumbai — 400051 Scrip Code: 524654 Symbol: NATCAPSUQ Subject: Investor Presentation Dear Sir/ Madam, Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of investor presentation in connection with the Unaudited Consolidated & Standalone Financial Results for quarter ended June 30, 2026. Request you to please take note of the same. Yours Faithfully, For Natural Capsules Limited Akshay Dutta Company Secretary and Compliance Officer M.No. A80481 Unit - I': Plot No. 7A2, KIADB Industrial Area, Attibele-562 107, Bangalore. Tel : 08110-645068, Fax : 080-27820325 Unit- I1: R.S. No. 84, Perambai Road, Pitchaiveeranpet, Pondicherry - 605 010. Tel : 0413-2290833, Fax : 0413-2293251 ( '\ "NHTURHL naturalcapsules.com CAPSULES S LIMITED Investor . Presentation BSE: 524654 AUGUST, 2026 NSE: NATCAPSUQ Safe Harbor Certain statements and opinions with respect to the anticipated future performance of Natural Capsules Limited (NCL) in the presentation (“forward - looking statements”), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward -looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward - looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward - looking statements only speak as at the date the presentation is provided to the recipient and NCL is not under any obligation to update or revise such forward - looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this presentation or that this presentation is suitable for the recipient’s purposes. The delivery of this presentation does not imply that the information herein is correct as at any time subsequent to the date hereof and Laxmi has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof. NOITATNESERP ROTSEVNI Inside this document QUARTERLY COMPANY BUSINESS HIGHLIGHTS OVERVIEW CANVAS FINANCIAL INVESTMENT PERFORMANCE MERITS NOITATNESERP ROTSEVNI aaaaaaaaaaaaaaaaaaa Quarterly Highlights Quarterly Updates — Q1FY27 (Consolidated) REVENUES X48.71 Cr EBITDA 1.12Cr ® (17%) Q-0-Q ® (16%) Q-0-Q ® 8% Y-0-Y ® 251% Y-o-Y EBITDA MARGINS 2.30% PAT (X5.74 Cr) ® 2BPS Q-0-Q ® 15%Q-0-Q ® 159 BPS Y-0-Y ® 3% Y-0-Y EPS (X 5.55) ® 15% Q-0-Q ® 3%Y-0-Y NOITATNESERP ROTSEVNI Management Commentary "QIFY27 was a strong operational quarftore thre capsules business. As communicated previously, the reported numbers are notdirectly comparable to the preceding quarter, which had benefited from the dispatch of deferred inventory following the Puducherry plant shutdown. On an underlying basis, however, the business delivered a healthy performance. During the quarter, we witnessed sustained demand across our capsule products alongside an improvement inrealisations. We were able to successfully navigate the rise in input costs through timely pass-throughs to customers, which supported margin preservation. The gelatine capsules business in particular delivered healthy margins, and we remain confident of sustaining this level of profitability through the remaindeorf the year. It is also worth noting that the implementation ofa new ERP system towards the close of the quarter resufted in a brief disuption to our biling and dispatch cycle, with sales in the final five days of Q1 being pushed into Q2. Absent this impact, the reported revefnoru tehe quarter would have been modestly higher. Separately, the depreciation of the rupee during the quarter provided a meaningful taiwind to our exportrealisations. We are pleased to report that demand trends have remained firm into Q2FY27, and we are confident of a sustained performance in the capsules busness through the financial year. On the HPMC segment, the demand environment in the US market has remained erratic, compounded by continued uncertainty aroundduty structures. Given these conditions, and with no material US export volumes during the quarter, we have taken the pragmatic decision to tenporarily convert one of our HPMC lines to a gelatine line in ortdo opetimrise capacity utilisation and protect overall profitability. A second HPMC line is expected to be similarly converted in the coming month. We will continue to monitor the US market environment and review our HPMC capacity deploymentaccordingly. On the APl business, QIFY27 presented a mixed picture. Ongoing geopolitical uncertainty weighed on business operations duringthe quarter. The concurrent appreciation of the Chinese yuan and depreciation of the Indian rupee created headwinds for our African export busness routed through merchant exporters, which moderated volumes in that segment. Notwithstanding these near-term pressures, we made meaningful operational and strategic progress. The first batch under our contract manufacturing agreement with Fermbox Bio commenced in August, marking an important milestone in that collaboration. We have additionally executed a new contract manufacturing agreement with a Mumbai-based client, further building our CMO pipeline. On the technical front, we successfully completed prednisolone synthesis at gram-scale batches during the quarter, and we expect to produce our first fully backward-integrated prednisolone batch by the end of September. Separately, one of our fermentation steps has been successfully transitioned to an enzymatic route, resulting in meaningfully improved yields and cost optimisation. These developments directly strengthen the unit economics of our API operations From a regulatory standpoint, WHO GMP application process has been initiated and we expect the associated audit to be conducted by the end of Q2FY27. We have also made an important leadership appointment, bringing on board a Chief Operating Offifcore trhe API business; a seasoned Sunil Mundra professional with over 30 years of industry experience, including a prior stint at Shilpa Medicare. This appointment reflectsour commitment to building the organisational depth required to scale this business meaningfully. MANAGING DIRECTOR We enter Q2FY27 with improved visibility across both segments. Our priorities are scaling API volumes, sustaining profitabilty in the capsules business, and NATURAL CAPSULES LIMITED progressing critical regulatory milestones. With a strengthened team and defined strategic direction in place, we remain confdent in the Company's ability to deliver sustained growth in the periods ahead.” NOITATNESERP ROTSEVNI Profi. t & Loss Statement Summary (consolidated) =: PARTICULARS ( IN CRORES) Q1FY26 QA4FY26 Q1FY27 Q-0-Q Y-o-Y E Revenue From Operations 45.20 58.45 48.71 -17% 8% = Other Income 036 076 235 208% 556% = Total Income 45.56 59.22 51.06 -14% 12% Total Operating Expenses 44.88 57.12 47.59 -17% 6% EBITDA 0.32 133 1.12 -16% 251% EBITDA Margins (Excluding Ol) 0.71% 2.28% 2.30% 2 BPS 159 BPS Depreciation and Amortisiation 421 428 433 1% 3% Finance Cost 253 2.89 [Showing first 8,000 characters — download PDF for full document]